Stage IIIC Cutaneous Melanoma AJCC v7 Recruiting Phase 2 Trials for Trametinib (DB08911)

DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Recruiting2 IdentifierTitlePurposeDrugs
NCT02910700Nivolumab and Trametinib With or Without Dabrafenib in Treating Patients With BRAF Mutated or Wild Type Metastatic Stage III-IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT02231775Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationTreatment